Bank counts on double-digit growth for Novo Nordisk in 2023
The Danish pharmaceutical company is on track to meet growth targets in the double digits for both 2022 and 2023, writes Jyske Bank, emphasizing factors like a positive flow of news and a well-defended stock.
by marketwire, translated by daniel pedersen
Danish bank Jyske bank sees a positive 2023 ahead of pharmaceutical firm Novo Nordisk, noting that the company’s stock will be walled off from an uncertain market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk invests over USD 740m in Danish facility
For subscribers
